Aspirin-exacerbated respiratory disease with recurrent polyps after three sinus surgeries
A 41-year-old woman is referred with 4 years of bilateral nasal obstruction, anosmia, and thick nasal discharge. She has had three endoscopic sinus surgeries, the most recent 14 months ago. She has asthma controlled with budesonide-formoterol and reports wheezing and facial flushing after ibuprofen. She has taken mometasone nasal spray and saline irrigations for 3 months, two 5-day courses of prednisolone 40 mg in the past year, and montelukast without sustained benefit. Endoscopy shows grade 3 bilateral nasal polyposis with mucopurulent secretions. CT shows a Lund-Mackay score of 21 with opacification of all sinuses and neo-osteogenesis. SNOT-22 score is 68; blood eosinophils 0.9 x 10^9/L; total IgE is normal; skin prick test is negative. She wants to avoid another operation if possible.
1. How do you classify her disease and what is the next step in medical management before considering revision surgery?
Read the worked answer
She has chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease, with type 2 inflammation evidenced by eosinophilia, asthma, and recurrent polyps. The next step is not simply another course of oral steroids. Optimize topical therapy with budesonide 0.5 mg/2 mL in 240 mL saline twice daily via squeeze bottle or high-volume irrigation, ensure correct technique, and continue saline. Check adherence and avoid NSAIDs. Because she has had three surgeries, a SNOT-22 of 68, and near-complete opacification, she meets criteria for a biologic; dupilumab is approved for CRSwNP, with omalizumab and mepolizumab as alternatives. Before starting, confirm asthma control. Consider aspirin desensitization only after adequate surgery, because it is less effective when polyps are still present. If she prefers surgery, revision endoscopic sinus surgery is also appropriate.
2. What is the role of revision endoscopic sinus surgery versus a biologic in this patient, and what factors tip the decision?
Read the worked answer
Revision surgery and biologics are complementary, not mutually exclusive. Surgery removes mechanical obstruction, opens sinus ostia, drains infection, and allows topical steroids to reach the mucosa; neo-osteogenesis and previous surgery make complete dissection harder. A biologic reduces type 2 inflammation and asthma exacerbations and is preferred when the patient has had repeated surgery, has a high symptom burden, or has contraindications to surgery. Factors tipping toward surgery first include a large mucocele, purulence, frontal recess obstruction, or the need for culture. Factors favoring a biologic first include severe asthma, previous good surgical result with rapid recurrence, or patient preference to avoid the operating room. In aspirin-exacerbated respiratory disease, aspirin desensitization after surgery can reduce recurrence, but it is not a substitute for topical therapy.
3. If she undergoes revision endoscopic sinus surgery, outline the intraoperative and postoperative plan to reduce recurrence.
Read the worked answer
Preoperatively, review CT for frontal recess anatomy, neo-osteogenesis, and skull base, and consent for frontal drillout. Intraoperatively, use image guidance, preserve mucosa where possible, completely remove polyps and open all sinuses, and send pus for culture. Postoperatively, start high-volume budesonide irrigations, avoid routine systemic antibiotics unless culture-positive infection, and schedule debridement at 1 and 3 weeks. Consider aspirin desensitization after the mucosa has healed, and reassess at 3-6 months. If recurrence persists despite optimized topical therapy and desensitization, start dupilumab. The key is to combine complete surgery with sustained anti-inflammatory therapy rather than relying on repeated short steroid courses.